Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017037578) PHARMACEUTICAL COMBINATION COMPRISING (A) THE ALPHA-ISOFORM SPECIFIC PI3K INHIBITOR ALPELISIB (BYL719) AND (B) AN AKT INHIBITOR, PREFERABLY MK-2206, AFURESERTIB OR UPROSERTIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/037578 International Application No.: PCT/IB2016/055049
Publication Date: 09.03.2017 International Filing Date: 24.08.2016
IPC:
A61K 31/4155 (2006.01) ,A61K 31/4375 (2006.01) ,A61K 31/4439 (2006.01) ,A61P 35/00 (2006.01)
[IPC code unknown for A61K 31/4155][IPC code unknown for A61K 31/4375][IPC code unknown for A61K 31/4439][IPC code unknown for A61P 35]
Applicants:
CAPONIGRO, Giordano [US/US]; US (US)
HORN-SPIROHN, Thomas [DE/US]; US (US)
LEHAR, Joseph [US/US]; US (US)
HIRAWAT, Samit [US/US]; US (US)
NOVARTIS AG [CH/CH]; Lichtstrasse 35 4056 Basel, CH (AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW)
Inventors:
CAPONIGRO, Giordano; US
HORN-SPIROHN, Thomas; US
LEHAR, Joseph; US
HIRAWAT, Samit; US
Agent:
RUECK, Sandra; US
Priority Data:
62/211,01428.08.2015US
Title (EN) PHARMACEUTICAL COMBINATION COMPRISING (A) THE ALPHA-ISOFORM SPECIFIC PI3K INHIBITOR ALPELISIB (BYL719) AND (B) AN AKT INHIBITOR, PREFERABLY MK-2206, AFURESERTIB OR UPROSERTIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER
(FR) POLYTHÉRAPIE
Abstract:
(EN) The present disclosure pertains to a pharmaceutical combination comprising (a) alpha- isoform specific PI3K inhibitor and (b) an AKT inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of such combination. 43
(FR) La présente invention concerne une combinaison pharmaceutique comprenant (a) un inhibiteur de PI3K spécifique à l'isoforme alpha et (b) un inhibiteur de AKT ; des compositions pharmaceutiques et des préparations combinées de ces derniers ; les utilisations d'une telle combinaison dans le traitement ou la prévention du cancer ; et des procédés de traitement ou de prévention du cancer chez un sujet en ayant besoin, comprenant l'administration d'une quantité thérapeutiquement efficace d'une telle combinaison.43
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)